GYANT, Cleveland Clinic partner to improve patient experience with AI

GYANT, a San Francisco-based healthcare technology company, has launched an expanded partnership with Cleveland Clinic aimed at improving patient communication.

GYANT’s AI-powered patient experience platform is now being used in 10 Cleveland Clinic locations, and the solution will soon be live within the company’s Women’s Health Institute to improve the care of new mothers. The platform was designed to help patients communicate with their providers, providing them with the help they need both in the hospital and after they’ve gone back home. Before this latest announcement, GYANT and Cleveland Clinic had already established a working relationship; the use of GYANT’s platform led to an improved patient contact rate.

“Health systems are under tremendous pressure today to provide ever-more convenient access to care for patients while tightly managing operational costs,” Pascal Zuta, CEO and co-founder of GYANT, said in a prepared statement. “We’re proud to help accomplish both of these goals and look forward to connecting patients digitally with their care teams throughout the patient journey.”

GYANT previously announced a new partnership with Minneapolis, Minnesota-based Zipnosis. AI in Healthcare coverage of that story is available here. Information on Cleveland Clinic’s top 10 medical innovations for 2020 can be read here.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.